Search

Your search keyword '"Kłos, Krzysztof"' showing total 132 results

Search Constraints

Start Over You searched for: Author "Kłos, Krzysztof" Remove constraint Author: "Kłos, Krzysztof"
132 results on '"Kłos, Krzysztof"'

Search Results

1. Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study)

2. Theoretical Study of Quaternary nBp InGaAsSb SWIR Detectors for Room Temperature Condition.

Catalog

Books, media, physical & digital resources

3. Pulmonary Function, Computed Tomography Lung Abnormalities, and Small Airway Disease after COVID-19: 3-, 6-, and 9-Month Follow-Up

4. Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration

5. MOCVD Growth of GaSb, InGaAsSb and AlGaAsSb

7. Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy

10. Does Hospitalization Change the Perception of COVID-19 Vaccines among Unvaccinated Patients?

11. Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland

13. COVID-19 i jego powikłania - przypadki kliniczne

15. Effectiveness of Hyperbaric Oxygen Therapy in SARS-CoV-2 Pneumonia: The Primary Results of a Randomised Clinical Trial.

17. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study

19. Impact of Kidney Failure on the Severity of COVID-19

22. Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6

23. Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis

25. Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study

27. A 63-Year-Old Man with a Diagnosis of Re-Infection with SARS-CoV-2 Nine Weeks After an Initial Hospital Admission with COVID-19 Pneumonia.

29. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.

30. How fast does wasp venom immunotherapy affect a regulatory T cell subpopulation (CD4+ CD25+ Foxp3+) and the synthesis of interleukins 10, 21 and transforming growth factor β1?

31. Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration

35. Treat-to-target therapy does not prevent excessive progression of carotid intima media thickness during the first year of therapy in early rheumatoid arthritis

38. Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis

40. Świadectwa o ks. Antonim Słomkowskim

43. Prevalence of Atherosclerosis in diabetic and non-diabetic patients with rheumatoid arthritis.

44. Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques -- a preliminary report. Beneficial effect of immunosuppressive treatment on carotid intima...

46. Nawracająca anafilaksja u chorej na astmę -- efekt rocznego leczenia omalizumabem.

47. Comparison of T cell maturation profiles in the 1st and 5th wave of COVID-19 in the Polish population.

48. Assessment of selected parameters of the circulatory system in patients undergoing oral aspirin challenge.

49. How fast does wasp venom immunotherapy affect a regulatory T cell subpopulation (CD4+ CD25+ Foxp3+) and the synthesis of interleukins 10, 21 and transforming growth factor β1?

50. Treat-to-target therapy does not prevent excessive progression of carotid intima media thickness during the first year of therapy in early rheumatoid arthritis.